Comorbidity and comedication burden among people living with HIV in the United States.

OBJECTIVE

To describe the burden of comorbid conditions and comedications among people living with HIV (PLWH) vs. people living without HIV (PLWoH).

METHODS

This was a case-control study conducted among insured patients using administrative claims data. Adult PLWH were identified by antiretroviral therapy (ART) claims or HIV/AIDS diagnosis codes from 1 January 2018 to 31 December 2018 (index date was set by the earliest claim). Continuous enrollment was required for ≥12 months pre-index (baseline) and ≥30 days post-index (follow-up). Patients were required to have ≥1 HIV diagnosis during baseline or follow-up. Those with only HIV prophylaxis were excluded. PLWoH were matched 2:1 to PLWH on demographic characteristics. Study outcomes were compared using -tests with robust standard errors in an ordinary least squares regression or Rao-Scott tests.

RESULTS

The study included 20,256 PLWH and 40,512 matched PLWoH, mean age 52 years. PLWH vs. PLWoH had higher mean (SD) Charlson comorbidity index scores (0.93 [1.59] vs. 0.61 [1.28];  < .001) and a greater proportion had ≥1 comorbidity (69.1% vs. 54.5%,  < .001). The most prevalent comorbidities included hypertension (33.9% vs. 32.2%;  < .001), hyperlipidemia (29.4% vs. 24.6%;  < .001), chronic kidney disease (13.6% vs. 9.4%,  < .001), depression (13.1% vs. 7.3%,  < .001) and substance abuse (12.8% vs. 7.1%,  < .001). Mean (SD) non-ART prescription fills were higher among PLWH vs. PLWoH (11.9 [10.1] vs. 9.2 [9.4];  < .001).

CONCLUSIONS

Multimorbidity and polypharmacy were more prevalent among PLWH vs. matched PLWoH. Findings support the need to consider comorbidities and comedications when choosing ART and to minimize drug-drug interactions and adverse events to improve patient outcomes.